Persistent COVID-19 Symptoms in Minia

Persistent COVID-19 Symptoms in Minia, Upper Egypt: an Observational Cross-sectional Study

Objective This study aims to identify the nature and prevalence of persistent symptoms in patients discharged from Minya University hospitals in Egypt after recovery from COVID-19, the severity of these symptoms, and the possible risk factors associated with them.

Study Overview

• Status: Completed
• Conditions: COVID - 19

Detailed Description

This is a cross-sectional observational retrospective study. The study population included patients, both hospitalized and non-hospitalized, who were diagnosed with COVID-19. Demographic information, symptom severity, present comorbidities, and persistent COVID-19 symptoms were collected. SPSS software was used for the statistical analysis, and p-values less than 0.05 were considered significant.

• Study Type: Observational
• Enrollment (Actual): 189

Contacts and Locations

Study Locations

• Egypt
  • Fayoum, Egypt, 63111
    • Marwa

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

This is a cross-sectional observational retrospective survey study in which we collected information about any persistent or new symptoms after recovery from COVID-19. The average time after recovery from COVID was 6 months at the time of patient interviews, and the median duration of symptoms was 14 days. We collected various patient data including their medical history before COVID-19, treatments they received during their illness, and self-reported use of unprescribed antibiotics in home-isolated patients.

Description

Inclusion Criteria:

- Inclusion criteria Patients were included in this study if they tested positive for COVID-19 at the time of their illness (positive COVID-19 polymerase chain reaction [PCR] test) or if laboratory, clinical, and radiological criteria suggested the infection with COVID-19, and the severity of their symptoms ranged from asymptomatic to severe. Both hospitalized and non-hospitalized patients were included.

Exclusion Criteria:

Exclusion criteria Patients excluded were frail or at the end of their life or had severe cognitive dysfunction, as well as patients <18 years of age.

-

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Long COVID-19 has been an increasingly prevalent concern in the medical community for the last two years and is still a burden on the healthcare system worldwide	Constitutional and neurological manifestations are two of the most persistent symptoms. Lack of appropriate levels of awareness about long COVID-19, as well as the tendency of patients in this demographic to self-medicate are leading causes of the underreporting of long COVID-19 symptoms in this region	2years

Collaborators and Investigators

• Sponsor: Fayoum University

Publications and helpful links

General Publications

• Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22.

Study record dates

Study Major Dates

• Study Start (Actual): March 10, 2021
• Primary Completion (Actual): September 10, 2023
• Study Completion (Actual): September 10, 2024

Study Registration Dates

• First Submitted: January 19, 2025
• First Submitted That Met QC Criteria: January 19, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 19, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Keywords: risk factors; covid19; self-medication
• Additional Relevant MeSH Terms: Post-Infectious Disorders; Pathologic Processes; Chronic Disease; Disease Attributes; Respiratory Tract Infections; Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Lung Diseases; Pneumonia, Viral; Pneumonia; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; COVID-19; Post-Acute COVID-19 Syndrome
• Other Study ID Numbers: : Persistent COVID-19 symptoms

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No